Cargando…
Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19
The proposed doses of chloroquine (CQ) and hydroxychloroquine (HCQ) for treatment of COVID-19 (1000 mg/day for 10 days, CQ; 800 mg first day then 400 mg/day for 5 days, HCQ) in many guidelines worldwide, are considerably higher than the maximum recommended daily safe doses of both agents (≤2.3 mg/kg...
Autores principales: | Ruamviboonsuk, Paisan, Lai, Timothy Y. Y., Chang, Andrew, Lai, Chi-Chun, Mieler, William F, Lam, Dennis S. C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227199/ https://www.ncbi.nlm.nih.gov/pubmed/32349115 http://dx.doi.org/10.1097/APO.0000000000000289 |
Ejemplares similares
-
Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19
por: Gevers, S., et al.
Publicado: (2020) -
Retinal toxicity to antimalarial drugs: chloroquine and hydroxychloroquine: a neurophysiologic study
por: Farrell, Donald F
Publicado: (2012) -
Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management
por: Lebin, Jacob A., et al.
Publicado: (2020) -
A review on the pharmacokinetic properties and toxicity considerations for chloroquine and hydroxychloroquine to potentially treat coronavirus patients
por: Askarian, Fatemeh, et al.
Publicado: (2021) -
Chloroquine and Hydroxychloroquine: Efficacy in the Treatment of the COVID-19
por: Ho, Tzu-Chuan, et al.
Publicado: (2021)